DIRS.INFO The most relevant business & tech news

☆ How VC Stephen Hays scraped his life off rock bottom after addiction and a bipolar diagnosis to tackle mental health stigma
▼ + stars: | 2024-07-29 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +10 min

Some parents had voiced concerns about Hays' "background," he told Business Insider. In 2020, he started What If Ventures, a venture firm focused on investing in mental health startups. Hays's new public persona as a staunch mental health advocate also puts a certain pressure on him to perform his recovery — "and I hate that," he said. He wants to show people struggling with their own mental health that working to get well is good enough. Advertisement"I don't just want to destigmatize addiction and mental health issues — I want to destigmatize the journey of getting better," he said.

Persons: —, Stephen Hays, Hays, couldn't, didn't, They'd, it's, Christine, he'd, Amit Etkin, Etkin, he'll, that's, Stephen, Christopher Kim, Kim, Hays doesn't, It's Organizations: Service, Little League baseball, Business, Neuroscience, Ventures, West, Space Ventures, Atlantic City, Magazine, Deep Space Ventures, Alto Neuroscience, BI, Argosy Strategic Partners, Argosy Locations: Dallas, Texas, Atlantic, Las Vegas, Colorado, Wickenburg , Arizona

☆ These are the 7 healthcare startups primed to IPO when the market reopens
▼ + stars: | 2024-01-29 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +2 min

Only one digital health startup went public in the US in 2022 — digital therapeutics company Akili Interactive, whose shares have since crashed a whopping 97%, per MarketWatch. Not a single healthcare startup went public last year. ArriVent Biopharma went public a few days later, bringing in $175 million. AdvertisementIndustry experts remain skeptical about whether the public markets will be ready for a successful healthcare IPO this year. Business Insider has identified seven startups that could be considering an IPO as the markets reopen, based on conversations with top VCs and bankers and public filings.

Persons: —, Metagenomi, ArriVent Biopharma Organizations: Service, Business, Akili Interactive, Alto Neuroscience, Oncology, BrightSpring Health Services, KKR, Walgreens, Industry

☆ 2023 has been an AI feeding frenzy, here are the startups that attracted the most investment this year
▼ + stars: | 2023-12-04 | by ( Darius Rafieyan | ) www.businessinsider.com time to read: +7 min

Despite an overall slump in startup funding, 2023 saw a scramble among investors to pour money into AI and machine learning startups. And the company's star still appears to be rising, despite a messy leadership struggle that recently spilled into public view. Meanwhile OpenAI's perennial rival Anthropic attracted multi-billion dollar investments from both Google and Amazon to fund a competing AI model known as Claude. At the same time legacy companies from John Deere to accounting firm PwC played up their AI bona fides to capitalize on the hype. The list doesn't include startups who have not publicly released the amount of their funding rounds.

Persons: OpenAI, Anthropic, Claude, Databricks, John Deere, PwC, Fresh Organizations: Microsoft, Google, Alpha, Technology, Monogram, Sigma, Lambda, Helsing, Metals, Eagle Eye, Amelia, Asimov, Farmers Business, Harbinger, Prins, Silo, Mistral, Alto, AMP, Management Software, Universal, Coro, Kodiak Robotics, Aerospace, Defense, Sana, Corti, Kyte, Mitra, Tech, Boss Digital Technology, Halcyon, & $ Locations: PitchBook

☆ Depression treatments haven't changed much in decades. Here are the promising new drugs that could be more precise, work faster, and help more people.
▼ + stars: | 2023-02-02 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +6 min

Advances in depression treatment have been rare over the past few decades. But treatments for mental-health illnesses, like depression, haven't changed much over the past few decades. Insider put together a roundup of the most promising depression treatments today, both those that have won approval and those that are in the later stages of the research process. Unlike most depression treatments on the market, Auvelity is rapid-acting, which means it offers faster relief for patients. MDD is also known as clinical depression and is defined by persistent depressive symptoms.

☆ A scientist quit Stanford to chase a new way to treat depression. He just shared an early sign that his approach could work.
▼ + stars: | 2023-01-10 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +3 min

Alto Neuroscience is focused on developing precision medicine for mental health. "The way we develop drugs, the way we deploy drugs in the clinic, all presume nothing about the patient," Etkin said. He said trial results from Alto were "the first of a series of studies, of a series of efforts," to change that approach. In the trial, Alto separated patients into groups with poor cognition and good cognition, based on a test the company developed, Etkin said. Alto Neuroscience.

☆ Cerebral is trying out an unusual clinical trial for a depression drug that has other companies wary. Here’s why.
▼ + stars: | 2022-01-14 | by ( Megan Hernbroth | ) www.businessinsider.com time to read: +6 min

The mental-health startup Cerebral partnered with Alto Neuroscience for a clinical trial. The mental-health startup Cerebral is teaming up with Alto Neuroscience on an upcoming home-based clinical trial for the biopharmaceutical company Alto's depression-drug candidate, according to federal records. The idea behind the partnership is that Cerebral is a mental-health company treating patients with depression, the condition for which Alto is developing treatments. Cerebral Chief Medical Officer David Mou told TechCrunch in December that the startup provided patients for the trial "within an hour." How Alto is running the trialThe trial with Cerebral does not include a control group, according to the filing.

Search resuls for: "Alto Neuroscience"

6 mentions found